NCT06787612 2026-04-08
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Regeneron Pharmaceuticals
Phase 2 Recruiting
Clinical Trials
6 trialsNCT06161025 2026-01-12
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Daiichi Sankyo
Phase 2/3 Recruiting
NCT05271318 2025-11-03
PROTA
TILT Biotherapeutics Ltd.
Phase 1/2 Recruiting
NCT05551507 2025-04-30
IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer
InxMed (Shanghai) Co., Ltd.
Phase 1/2 Recruiting
NCT06014528 2025-04-30
IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer
InxMed (Shanghai) Co., Ltd.
Phase 2 Recruiting
NCT06687070 2025-02-26
APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST
Ascentage Pharma Group Inc.
Phase 1 Recruiting